<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-043416</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Empirical antifungal therapy in selected patients with persistent fever and neutropenia</dc:title>
<dc:description xml:lang="en">Empirical antifungal treatment (EAT) in neutropenia is mainly aimed at improving the poor prognosis of patients with invasive fungal infection through early treatment. The Infectious Diseases Society of America recommends initiating EAT in patients with persistent fever after 5-7 days of antibacterial treatment, and in those in whom remission of neutropenia is not imminent. Nevertheless, EAT has not been shown to be more effective than a placebo, it does not show better results than directed antifungal treatment, its effectiveness is minimal, it is not innocuous, and it is not very efficient with the use of most antifungal agents. All considered, we believe that the aforementioned recommendation for EAT treatment is unjustified. In its place we propose the application of EAT in patients selected on the basis of clinical criteria and risk factors (AU)</dc:description>
<dc:creator>Rivero, Antonio</dc:creator>
<dc:creator>Cisneros, José Miguel</dc:creator>
<dc:creator>Espigado, Ildefonso</dc:creator>
<dc:creator>Parra, Jorge</dc:creator>
<dc:creator>Lomas, José Manuel</dc:creator>
<dc:creator>Pachón, Jerónimo</dc:creator>
<dc:creator>Collado, Antonio Ramón</dc:creator>
<dc:creator>Lozano de León, Fernando</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tratamiento antifúngico empírico (TAE) en los pacientes con neutropenia tiene como objetivo principal mejorar el mal pronóstico de los pacientes con infección fúngica invasora, mediante el tratamiento precoz de la misma. La Sociedad Americana de Enfermedades Infecciosas recomienda iniciar el TAE en los pacientes con fiebre después de 5-7 días de tratamiento antibacteriano y en los que la resolución de la neutropenia no es inminente. Sin embargo, el TAE no ha demostrado mayor eficacia que el placebo, no obtiene mejores resultados que el tratamiento antifúngico dirigido, su efectividad es mínima, no es inocuo y, con la mayoría de los antifúngicos, es muy poco eficiente. Por todas estas razones consideramos que la citada recomendación del TAE no está justificada. En su lugar proponemos la realización del TAE en pacientes seleccionados por criterios clínicos y factores de riesgo (AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;23(10): 609-614, dic. 2005. ilus, tab</dc:source>
<dc:identifier>ibc-043416</dc:identifier>
<dc:title xml:lang="es">Tratamiento antifúngico empírico en pacientes seleccionados con fiebre persistente y neutropenia</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d9691^s22057</dc:subject>
<dc:subject>^d9691^s22036</dc:subject>
<dc:subject>^d1948^s22057</dc:subject>
<dc:subject>^d1948^s22046</dc:subject>
<dc:subject>^d3901^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d943^s22073</dc:subject>
<dc:subject>^d9373^s22080</dc:subject>
<dc:subject>^d943^s22020</dc:subject>
<dc:subject>^d32095</dc:subject>
<dc:subject>^d974^s22020</dc:subject>
<dc:subject>^d9562^s22012</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d32383^s22057</dc:subject>
<dc:subject>^d32383^s22046</dc:subject>
<dc:subject>^d5444^s22027</dc:subject>
<dc:subject>^d9373^s22057</dc:subject>
<dc:subject>^d5444^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200512</dc:date>
</metadata>
</record>
</ibecs-document>
